 |
For Most Mild to Moderate Crohn's Patients
ENTOCORT® EC is maintenance therapy*
No greater incidence of glucocorticosteroid (GCS)-related side effects in patients treated continuously for 12 months vs 8 weeks2
)
Lower recurrence of symptoms at 3 months2,9
)
Data from a pooled analysis of 4 12-month, randomized, double-blind, placebo-controlled, multicenter studies of 380 patients with medically induced remission of mild to moderate Crohn’s disease involving the ileum and/or ascending colon. Adapted from Sandborn et al, Am J Gastroenterol and ENTOCORT EC PI.2,9
**Long-term therapy is defined as induction, maintenance, and re-treatment for recurring active episodes of disease.
*For Crohn’s disease involving the ileum and/or ascending colon, ENTOCORT EC is indicated for the treatment of mild to moderate active disease (up to 8 weeks with repeated 8-week courses as necessary) and the maintenance of clinical remission of mild to moderate disease for up to an additional 3 months.
Clinical remission is defined as a Crohn’s Disease Activity Index (CDAI) score of ≤150.
Important safety information
Since ENTOCORT EC® is a glucocorticosteroid (GCS), general warnings about GCSs should be followed. GCSs can reduce the response of the hypothalamus-pituitary-adrenal axis to stress. Supplementation with a systemic GCS is recommended before surgery or other stress situations. Adrenocortical function monitoring may be required in patients being transferred to ENTOCORT EC from a systemic GCS, and the dose of the systemic GCS should be reduced cautiously.
Patients on drugs that suppress the immune system are more susceptible to infections and should avoid exposure to infections such as chicken pox or measles.
Patients with moderate to severe liver disease and patients who are concomitantly taking ketoconazole or any other CYP3A4 inhibitor should be closely monitored for increased signs and/or symptoms of hypercorticism.
The adverse event profile of ENTOCORT EC in 6 mg once daily clinical trial treatment (52-week) was similar to that of 9 mg once daily clinical trial treatment (8-week). The most frequently reported adverse events in clinical trials of ENTOCORT EC were headache, respiratory infection, nausea, and symptoms of hypercorticism.
